SavedAdd your journal

Journals / İzmir Göğüs Hastanesi Dergisi / 2020 / Cilt: 34 - Sayı: 1

Characteristics of Pulmonary Arterial Hypertension Patients and Evaluation of Factors Affecting Treatment Response and Survival

Pulmoner Arteriyel Hipertansiyon Olgularının Özellikleri, Tedavi Yanıtına ve Sağkalıma Etkili Faktörlerin Değerlendirilmesi

Bilge YIlMAZ KARA
Benan MüSEllİM
Gül ÖNGEN
Pages
1–11
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Compared to iloprost, bosentan group had lower stage of WHO-FC (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Method:The data of patients followed up with PAH between 2005 and 2012 were reviewed retros-pectively.
📊
Key Findings & Data:Patients younger than 18 years of age, patients who belong to other pulmonary hypertension groups other than group 1, and those with malignancy were excluded.
💡
Conclusion & Impact:Compared to iloprost, bosentan group had lower stage of WHO-FC (p
🔬Design:Review & Systematic Survey
📍Scope:2005 Verileri
⚙️Variables:Domain Parameters

Abstract

Method:The data of patients followed up with PAH between 2005 and 2012 were reviewed retros-pectively. The patients were grouped as PAH associated with connective tissue disease (CTD), idiopat-hic PAH (IPAH) and PAH due to congenital heart disease (CHD). Patients younger than 18 years of age, patients who belong to other pulmonary hypertension groups other than group 1, and those with malignancy were excluded. Demographic data, drugs used in treatment, functional class according to World Health Organization Functional Classification (WHO-FS), 6-minute walking distance (6MWD) and hemodynamic parameters at baseline and follow-up were obtained from the patient files. The primary endpoint of the follow-up was determined as death.Results:Totally 43 PAH patients (F/M:35/8, median (IQR: Interquartile range): 57 (16) years) were enrolled. In the etiology 22 patients had CTD, 15 patients had IPAH, and 6 patients had CHD. During the median (IQR) follow-up period of 23 (25,7) months, 20 (46.5%) patients died. The mortality rates of etiological groups were similar. Compared to iloprost, bosentan group had lower stage of WHO-FC (p

Özet

Amaç:Çalışmamızda pulmoner arteriyel hipertansiyon (PAH) tanılı hastaların klinik özelliklerinin, teda-vi etkinliğinin ve sağkalıma etkili faktörlerin saptanmasını amaçladık.Yöntem: 2005-2012 yılları arasında PAH tanısıyla takip edilen hastaların verileri retrospektif olarak incelendi. Hastalar; bağ dokusu hastalığına bağlı PAH (BDH), idiyopatik PAH (İPAH) ve doğumsal kalp hastalığına bağlı PAH (DKH) olarak gruplandırıldı.On sekiz yaşından küçük olanlar, ESC/ERS kılavuzu klinik sınıflamasına göre grup 1 dışındakiler ve malignitesi olanlar çalışmadan dışlandı. Demografik veriler, tedavide kullanılan ilaçlar, başlangıç ve takiplerdeki Dünya Sağlık Örgütü Fonksiyonel Sınıflaması (DSÖ-FS), 6 dakika yürüme mesafesi (6DYM) ve hemodinamik parametreleri hasta dosyalarından elde edildi. Takipte primer sonlanım noktası ölüm olarak belirlendi. Bulgular:Çalışmaya toplam 43 hasta (K/E:35/8, medyan (çeyrekler arası genişlik) yaş: 57 (16) yıl) alındı. Etyolojide 22 hastada BDH, 15 hastada İPAH, 6 hastada KKH saptandı. Medyan (çeyrekler arası genişlik) 23 (25,7) ay takip süresinde 20 (%46,5) hasta öldü. PAH etyoloji grupları arasında mortalite açısından fark görülmedi. Sağkalım süreleri başlangıç tedavisi olarak bosentan alanlarda inhaler iloprost alanlara göre daha uzun (ortalama 53,9±6,4 ay’a karşılık 18,8±4,9 ay, p= 0,001), başlangıç DSÖ-FS evresi ileri olanlarda ise daha kısa saptandı (DSÖ-FS II ve IV için sırasıyla ortalama 40,7±4,3 ay’a karşı-lık 13,4±4 ay, p

🔖

Cite This Article

KARA, B. Y., MüSEllİM, B., ÖNGEN, G. (2022). Characteristics of Pulmonary Arterial Hypertension Patients and Evaluation of Factors Affecting Treatment Response and Survival. İzmir Göğüs Hastanesi Dergisi, Cilt: 34 - Sayı: 1, 1–11. https://ajindex.com/articles/557833

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. imonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definiti-ons and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53:1801913.https://doi.org/10.1183/13993003.01913-2018 2. Bergemann R, Allsopp J, Jenner H, Daniels FA, Drage E, Samyshkin Y, et al. High levels of healthcare utilization prior to diagnosis in idiopathic pulmonary arterial hyper-tension support the feasibility of an early diagnosis algo-rithm: The SPHInX project. Pulm Circ. 2018;8(4):1-9.https://doi.org/10.1177/2045894018798613 3. Öngen Z, Öngen G. Pulmoner Arteriyel Hipertansiyon Tedavisinde Yeni Ufuklar. Kaymaz C, Küçükoğlu M.S. Pulmoner Hipertansiyon. Aves Yayıncılık 2012:347-355. 4. Matsubara H, Ogawa A. Treatment of idiopathic/heredi-tary pulmonary arterial hypertension. J Cardiol. 2014;64(4): 243-9.https://doi.org/10.1016/j.jjcc.2014.06.009 5. Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J. 2009;(34):888-94.https://doi.org/10.1183/09031936.00145608 6. Simonneau G, Gatzoulis M.A, Adatia I, Celermajer D, Denton C, Ghofrani A, et al. Updated clinical classification of pulmonary hypertension, J Am Coll Cardiol. 2013;62 (25):34-41.https://doi.org/10.1016/j.jacc.2013.10.029 7. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. “2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hyperten-sion of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).” Eur Heart J. 2015;37(1):67-119.https://doi.org/10.1093/eurheartj/ehv317 8. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Pulmonay arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173(9):1023-30.https://doi.org/10.1164/rccm.200510-1668OC 9. Thenappan T, Shah SJ, Rich S and Gomberg-Maitland M. A USA-based registry for pulmonary arterial hypertensi-on: 1982-2006. Eur Respir J. 2007;30(6):1103-10.https://doi.org/10.1183/09031936.00042107 10. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Primary pulmonary hipertansion. A national prospective study. Ann Intern Med 1987;107(2):216-23